Aliskiren and Amlodipine and benazepril interaction

Aliskiren and Amlodipine and benazepril: both prescribing labels flag this combination with the strongest language, such as a contraindication, a boxed warning, or an instruction to avoid it.

Major

Do not combine without a prescriber's guidance. The label language below is the strongest FDA uses.

What the FDA labels say

From the Aliskiren label · effective 2022-12-30

Major

Do not use with angiotensin receptor blockers (ARBs) or angiotensin-converting enzyme inhibitors (ACEIs) in patients with diabetes.

Contraindicationsby drug classView label on DailyMed
Major

In general, avoid combined use of aliskiren with ACE inhibitors or ARBs, particularly in patients with creatinine clearance (CrCl) less than 60 mL/min [see Contraindications (4) , Drug Interactions (7) and Clinical Studies (14.3) ] .

Warnings and precautionsby drug classView label on DailyMed
Major

In general, avoid combined use of aliskiren with ACE inhibitors or ARBs, particularly in patients with CrCl less than 60 mL/min.

Drug interactionsby drug classView label on DailyMed

From the Amlodipine and benazepril (Amlodipine and Benazepril Hydrochloride) label · effective 2026-01-29

Major

Do not coadminister aliskiren with angiotensin receptor blockers (ARBs), angiotensin-converting enzyme (ACE) inhibitors, including amlodipine and benazepril hydrochloride capsules in patients with diabetes.

Contraindicationsnames AliskirenView label on DailyMed
Major

Do not coadminister aliskiren with ACE inhibitors, including amlodipine and benazepril hydrochloride capsules, in patients with diabetes.

Contraindicationsnames AliskirenView label on DailyMed
Major

Do not coadminister aliskiren with amlodipine and benazepril hydrochloride in patients with diabetes.

Drug interactionsnames AliskirenView label on DailyMed
Major

Avoid use of aliskiren with amlodipine and benazepril hydrochloride in patients with renal impairment [glomerular filtration rate (GFR) < 60 mL/min].

Drug interactionsnames AliskirenView label on DailyMed
Moderate

Dual Blockade of the Renin-Angiotensin System (RAS): Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy.

Drug interactionsnames AliskirenView label on DailyMed

Taking more than these two? Interactions stack. Check your whole list at once; it stays in your browser.

Open in the checker

Not medical advice. Interaction Checker quotes FDA label text and NIH fact sheets. Whether an interaction matters for you depends on doses, timing, kidney and liver function, and other conditions. Confirm with a pharmacist or prescriber.